Halozyme Therapeutics Inc

Common Name

Halozyme Therapeutics

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

350

Ticker

HALO

Exchange

NASDAQ/NGS

Website

www.halozyme.com

Description

Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary techno... Show more

Financial Statements of Halozyme Therapeutics

Below are the financial statements of Halozyme Therapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in millions of USD	2024	2023
Current assets	—	—
Cash and cash equivalents	115.85^a	118.37^a
Marketable securities, available-for-sale	480.22^a	217.63^a
Accounts receivable, net and contract assets	308.46^a	234.21^a
Inventories	141.86^a	127.6^a
Prepaid expenses and other current assets	38.95^a	48.61^a
Total current assets	1,085.34^a	746.42^a
Assets	—	—
Property and equipment, net	75.04^a	74.94^a
Prepaid expenses and other assets	80.6^a	17.82^a
Goodwill	416.82^a	416.82^a
Intangible assets, net	401.83^a	472.88^a
Deferred tax assets, net	3.86^a	4.39^a
Total assets	2,063.48^a	1,733.27^a
Current liabilities	—	—
Accounts payable	10.25^a	11.82^a
Accrued expenses	128.85^a	100.68^a
Total current liabilities	139.1^a	112.49^a
Liabilities and stockholders’ equity	—	—
Long-term debt, net	1,505.8^a	1,499.25^a
Other long-term liabilities	54.76^a	37.72^a
Total liabilities	1,699.66^a	1,649.46^a
Stockholders’ equity	—	—
Preferred stock	0^a	0^a
Common stock	0.12^a	0.13^a
Additional paid-in capital	0^a	2.41^a
Accumulated other comprehensive income (loss)	3.83^a	-9.28^a
Retained earnings	359.87^a	90.55^a
Total stockholders’ equity	363.82^a	83.81^a
Total liabilities and stockholders’ equity	2,063.48^a	1,733.27^a

Verified Sources Behind Halozyme Therapeutics’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Halozyme Therapeutics’s data sources below and access millions more through our Disclosure Search.

a. Halozyme Therapeutics's 10-K 2024

Trace every data point back to Halozyme Therapeutics’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Halozyme Therapeutics Inc

Financial Statements of Halozyme Therapeutics

Verified Sources Behind Halozyme Therapeutics’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

BioMarin Pharmaceutical Inc

Royalty Pharma PLC

Moderna Inc

Axsome Therapeutics Inc

Insmed Inc

Apellis Pharmaceuticals Inc